1. Home
  2. KALA vs PCLA Comparison

KALA vs PCLA Comparison

Compare KALA & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • PCLA
  • Stock Information
  • Founded
  • KALA 2009
  • PCLA 2008
  • Country
  • KALA United States
  • PCLA Japan
  • Employees
  • KALA N/A
  • PCLA N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • KALA Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • KALA Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • KALA 26.2M
  • PCLA 71.3M
  • IPO Year
  • KALA 2017
  • PCLA 2025
  • Fundamental
  • Price
  • KALA $5.86
  • PCLA $3.25
  • Analyst Decision
  • KALA Strong Buy
  • PCLA
  • Analyst Count
  • KALA 3
  • PCLA 0
  • Target Price
  • KALA $14.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • KALA 123.2K
  • PCLA 2.4M
  • Earning Date
  • KALA 08-05-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • KALA N/A
  • PCLA N/A
  • EPS Growth
  • KALA N/A
  • PCLA N/A
  • EPS
  • KALA N/A
  • PCLA N/A
  • Revenue
  • KALA N/A
  • PCLA $5,475,228.00
  • Revenue This Year
  • KALA N/A
  • PCLA N/A
  • Revenue Next Year
  • KALA N/A
  • PCLA N/A
  • P/E Ratio
  • KALA N/A
  • PCLA N/A
  • Revenue Growth
  • KALA N/A
  • PCLA 40.19
  • 52 Week Low
  • KALA $2.92
  • PCLA $0.37
  • 52 Week High
  • KALA $11.20
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • KALA 60.68
  • PCLA N/A
  • Support Level
  • KALA $4.36
  • PCLA N/A
  • Resistance Level
  • KALA $7.00
  • PCLA N/A
  • Average True Range (ATR)
  • KALA 0.71
  • PCLA 0.00
  • MACD
  • KALA 0.16
  • PCLA 0.00
  • Stochastic Oscillator
  • KALA 63.97
  • PCLA 0.00

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: